More Obesity Setbacks For Amylin And Takeda
This article was originally published in The Pink Sheet Daily
Executive Summary
A Phase II trial for their Symlin-based combination therapy was halted after safety issues cropped up with patients from a previous study.
You may also be interested in...
Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty
Discontinuation is unrelated to prior safety suspension, say Amylin and Takeda, who acknowledge that "this is a difficult time for innovators and regulators."
Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty
Discontinuation is unrelated to prior safety suspension, say Amylin and Takeda, who acknowledge that "this is a difficult time for innovators and regulators."
EMA Gives Nod To Bydureon, Approves Additional Indication For Pradaxa
The CHMP has recommended Bydureon for authorization, despite reservations having been expressed by FDA. An additional indication for Pradaxa was also recommended, boosting the drug's profile as a potential blockbuster.